Annual report
4368.TEDINET S100R3LC
Period2022-04-01 → 2023-03-31
Filed2023-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100RH5I (2023-07-28).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥68.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥55.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥42.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥41.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥42.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥18.9bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥15.0bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥19.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥15.5bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥9.7bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.9bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥15.7bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥10.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.0bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥14.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥10.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥113.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥92.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥76.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥64.5bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥26.0bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥16.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥87.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥75.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥66.2bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥60.3bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥55.3bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥24.2bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥22.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥10.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥13.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥13.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥9.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥15.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥400.9 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥308.08 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥191.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥197.56 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.81 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,482.8 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,136.65 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,863.74 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,698.11 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,558.77 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 77.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.1% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 17.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.4% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.1% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 859 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 805 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 794 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 781 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 761 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥57.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥46.2bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥35.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥34.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥34.5bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥15.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥12.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥17.6bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥9.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥17.9bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥14.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.0bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥10.2bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥6.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥7.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥103.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥84.0bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥69.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥63.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥58.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥25.0bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥16.6bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥78.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥67.4bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥60.2bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥54.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥49.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥17.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥20.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥370.05 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥287.48 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.88 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.76 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.55 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥63 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,215.9 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,913.17 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,696.88 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,547.58 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,405.37 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 75.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.5% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 17.9% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.8% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.7% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 35,511,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,511,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 538 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 491 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 481 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 467 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 445 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥82m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥143m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥21.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.9bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥19.5bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | employees | at 2023-03-31 | 312 pure |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥30.7bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥30.7bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment assets | at 2023-03-31 | ¥54.1bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥13.4bn |
| Life Science Business Unitreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Life Science Business Unitreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Life Science Business Unitreportable segment | employees | at 2023-03-31 | 501 pure |
| Life Science Business Unitreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥37.8bn |
| Life Science Business Unitreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥37.8bn |
| Life Science Business Unitreportable segment | segment assets | at 2023-03-31 | ¥37.7bn |
| Life Science Business Unitreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥7.4bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥20.8bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥68.5bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥68.5bn |
| —segment total | segment assets | at 2023-03-31 | ¥91.7bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥20.8bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥303m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥74m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥23.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.5bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥10.0bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥24.3bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥24.3bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment assets | at 2022-03-31 | ¥34.2bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥11.6bn |
| Life Science Business Unitreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| Life Science Business Unitreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Life Science Business Unitreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥31.4bn |
| Life Science Business Unitreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥31.4bn |
| Life Science Business Unitreportable segment | segment assets | at 2022-03-31 | ¥33.9bn |
| Life Science Business Unitreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥4.9bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥12.2bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥55.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥55.8bn |
| —segment total | segment assets | at 2022-03-31 | ¥68.2bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥16.6bn |
| Electronic Materials And Functional Chemicals Business Unitreportable segment | employees | at 2023-03-31 | 300 pure |
| Life Science Business Unitreportable segment | employees | at 2023-03-31 | 192 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,610
| Item | Context | Value | Unit |
|---|---|---|---|
| Write downs of inventories | CurrentYearDuration | 227424000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 688366000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 845085000 | JPY |
| Haulage expenses sga | Prior1YearDuration | 2113335000 | JPY |
| Haulage expenses sga | CurrentYearDuration | 2234041000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 1666828000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 1985557000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 579778000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 777587000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 84542000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 98117000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 132770000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 71800000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 31430947000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 24329534000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 55760482000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 55760482000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 31430947000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 24329534000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 55760482000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YearDuration | 55760482000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 4940194000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 11612139000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 16552334000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -1517573000 | JPY |
| Operating income | Prior1YearDuration | 15034761000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 33931963000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 34225450000 | JPY |
| Assets | Prior1YearInstant_ReportableSegmentsMember | 68157414000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 23852088000 | JPY |
| Assets | Prior1YearInstant | 92009502000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 1494994000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 2884417000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReportableSegmentsMember | 4379411000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReconcilingItemsMember | 73987000 | JPY |
| Depreciation segment information | Prior1YearDuration | 4453399000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | － | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | － | JPY |
| Impairment loss el | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Impairment loss el | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Impairment loss el | Prior1YearDuration | － | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E01056-000LifeScienceBusinessUnitReportableSegmentsMember | 2225839000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E01056-000ElectronicMaterialsAndFunctionalChemicalsBusinessUnitReportableSegmentMember | 9964410000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |